Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mo-Rez versus physician's choice chemotherapy in advanced or recurrent endometrial cancer
NL-OMON61628Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mocertatug rezetecan in endometrial cancer (EC) (2 arms), sponsored by GSK. Primary endpoints: Objective response rate by BICR and Progression-free survival by BICR. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON61628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61628.